Zomedica Corp. (ZOM): Price and Financial Metrics

Zomedica Corp. (ZOM): $0.16

0.01 (-3.60%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

F

ZOM Price/Volume Stats

Current price $0.16 52-week high $0.34
Prev. close $0.17 52-week low $0.15
Day low $0.16 Volume 3,543,100
Day high $0.17 Avg. volume 5,115,015
50-day MA $0.17 Dividend yield N/A
200-day MA $0.20 Market Cap 159.93M

ZOM Stock Price Chart Interactive Chart >

ZOM Stock Summary

  • For ZOM, its debt to operating expenses ratio is greater than that reported by only 9.26% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.06 for ZOMEDICA CORP; that's greater than it is for merely 7.91% of US stocks.
  • As for revenue growth, note that ZOM's revenue has grown 42.44% over the past 12 months; that beats the revenue growth of 89.16% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to ZOMEDICA CORP, a group of peers worth examining would be SIBN, MLSS, CDXC, SANM, and LPRO.
  • Visit ZOM's SEC page to see the company's official filings. To visit the company's web site, go to www.zomedica.com.

ZOM Valuation Summary

  • In comparison to the median Healthcare stock, ZOM's price/sales ratio is 86.84% higher, now standing at 7.1.
  • Over the past 73 months, ZOM's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ZOM.

Stock Date P/S P/B P/E EV/EBIT
ZOM 2023-11-20 7.1 0.7 -11.8 -8.8
ZOM 2023-11-17 6.8 0.6 -11.3 -8.4
ZOM 2023-11-16 6.7 0.6 -11.0 -8.1
ZOM 2023-11-15 6.9 0.6 -11.4 -8.4
ZOM 2023-11-14 7.0 0.6 -11.6 -8.7
ZOM 2023-11-13 7.3 0.7 -12.2 -9.1

ZOM Growth Metrics

    Its 3 year price growth rate is now at -36.09%.
  • Its 5 year cash and equivalents growth rate is now at -56.59%.
  • Its 5 year net cashflow from operations growth rate is now at -131.01%.
Over the past 46 months, ZOM's revenue has gone up $16,853,792.

The table below shows ZOM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 16.85379 -14.18835 -18.31899
2022-06-30 12.10031 -16.41631 -18.83468
2022-03-31 7.869999 -14.10782 -18.23235
2021-12-31 4.133123 -14.27516 -18.38317
2021-09-30 0.052331 -12.05688 -19.26638
2021-06-30 0.029817 -12.72155 -17.90067

ZOM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZOM has a Quality Grade of F, ranking ahead of 3.62% of graded US stocks.
  • ZOM's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ZOM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 -0.393 -5.936
2021-03-31 0 0.599 -5.609
2020-12-31 0 NA -5.395
2020-09-30 0 NA -6.260
2020-06-30 0 NA -6.329
2020-03-31 0 NA -5.504

Zomedica Corp. (ZOM) Company Bio


Zomedica Pharmaceuticals Corp. operates as a veterinary pharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of drugs, novel drug delivery systems, devices, and diagnostics for the health and wellness of companion animals, such as canine, feline, and equine. The company has a research collaboration agreement with Celsee Diagnostics, Inc. to test the feasibility of Celsee's liquid biopsy technology for veterinary application as a canine cancer diagnostics. Zomedica Pharmaceuticals Corp. was founded in 2015 and is based in Ann Arbor, Michigan.


ZOM Latest News Stream


Event/Time News Detail
Loading, please wait...

ZOM Latest Social Stream


Loading social stream, please wait...

View Full ZOM Social Stream

Latest ZOM News From Around the Web

Below are the latest news stories about ZOMEDICA CORP that investors may wish to consider to help them evaluate ZOM as an investment opportunity.

Zomedica to Present at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference

ANN ARBOR, MI / ACCESSWIRE / November 28, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today announced that ...

Yahoo | November 28, 2023

Zomedica to Present at the 35th Annual Piper Sandler Healthcare Conference

ANN ARBOR, MI / ACCESSWIRE / November 20, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today announced that ...

Yahoo | November 20, 2023

Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies

ANN ARBOR, MI / ACCESSWIRE / November 13, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported consolidated ...

Yahoo | November 13, 2023

Zomedica to Report Third Quarter 2023 Financial Results and Provide Business Update on November 13 at 4:30 p.m. ET

ANN ARBOR, MI / ACCESSWIRE / November 2, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for companion animals, will host a conference ...

Yahoo | November 2, 2023

Zomedica to Participate in the Lytham Partners Fall 2023 Investor Conference

ANN ARBOR, MI / ACCESSWIRE / October 11, 2023 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that Larry Heaton, Chief ...

Yahoo | October 11, 2023

Read More 'ZOM' Stories Here

ZOM Price Returns

1-mo -13.14%
3-mo -11.26%
6-mo -18.16%
1-year -14.44%
3-year -6.92%
5-year -89.26%
YTD -1.84%
2022 -46.82%
2021 32.91%
2020 -30.33%
2019 -73.09%
2018 -37.88%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!